Corbus Pharmaceuticals Holdings (LTS:0SZI) Short Percentage of Float


LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
47 GF Score
Price $9.61
GF Value $1.01
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0SZI vs PRQR, NRXP, CRBU: Short Percentage of Float Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Short Percentage of Float falls into.


LTS:0SZI
47GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of $9.61 is trading 851.5% above its estimated GF Value™ of $1.01. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for LTS:0SZI:

  • Short Percentage of Float:
  • GF Value™: $1.01 vs. price of $9.61 (851.5% above fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
47GF Score

Get the complete analysis for LTS:0SZI

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.61
Price
$1.01
GF Value